ORIC Pharmaceuticals Announces Pricing of Initial Public OfferingAraceli Richardson2020-08-18T00:57:30-07:00April 23, 2020|
Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung CancerAraceli Richardson2020-08-18T00:57:30-07:00February 21, 2020|
Black Diamond Therapeutics Announces Pricing of Initial Public OfferingAraceli Richardson2020-08-18T00:57:30-07:00January 29, 2020|
Black Diamond Therapeutics Closes $85 Million Series C FinancingAraceli Richardson2020-08-18T00:57:30-07:00December 5, 2019|
Boundless Bio Launches to Deliver Transformative Therapies to Patients with Difficult-to-Treat Cancers Driven by Extrachromosomal DNAAraceli Richardson2020-08-18T00:57:30-07:00September 19, 2019|
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumorAraceli Richardson2020-08-18T00:57:30-07:00August 15, 2019|
ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer ResistanceAraceli Richardson2020-08-18T00:57:31-07:00August 8, 2019|
Japan becomes the first country to approve Roche’s personalised medicine RozlytrekAraceli Richardson2020-08-18T00:57:31-07:00June 18, 2019|
OncoMyx Therapeutics Completes $25 Million Series A FinancingAraceli Richardson2020-08-18T00:57:31-07:00June 5, 2019|
Inhibrx Announces $40M Investment from Viking Global InvestorsAraceli Richardson2020-08-18T00:57:31-07:00May 21, 2019|
Erasca™ Announces Series A Extension, Bringing Total Round to $64 MillionAraceli Richardson2020-08-18T00:57:31-07:00March 5, 2019|
